ADMA
NASDAQ · Biotechnology
Adma Biologics Inc
$8.70
+0.01 (+0.12%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-54.88%
1Y
-51.26%
YTD
-51.34%
Open$8.73
Previous Close$8.69
Day High$8.86
Day Low$8.65
52W High$20.46
52W Low$7.21
Volume—
Avg Volume4.01M
Market Cap1.93B
P/E Ratio11.65
EPS$0.68
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$17.86
Below
SMA 200
$17.61
Below
RSI (14)
42.2
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
10 analysts
Price Target
+304.8% upside
Current
$8.70
$8.70
Target
$35.22
$35.22
$21.76
$35.22 avg
$46.82
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 482.81M | 323.94M | 922.90M |
| Net Income | 139.04M | 83.96M | -95,808,796 |
| Profit Margin | 28.8% | 27.4% | -10.4% |
| EBITDA | 178.16M | 113.56M | -107,012,515 |
| Free Cash Flow | — | — | -83,155,340 |
| Rev Growth | +49.0% | +49.0% | +20.1% |
| Debt/Equity | 0.15 | 0.15 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |